Aurobindo Pharma announced the product's launch in September 2023
The product will be available from September 2023 onwards.
In April-June 2023-24, the pharmaceutical company declared a net profit of Rs 520.5 crore.
It is a generic version of Hill Dermaceuticals Inc.'s Derma-Smoothe/FS 0.01% (Body Oil).
The company's consolidated profit after tax exhibited an 86 % sequential drop from Rs 26.55 crore.
The company plans to launch the product in August 2023.
The 'Official Action Indicated' status may cause product approvals to be delayed or withheld.
The Hamied family's eventual exit from the pharma company will begin.
The drugmaker's EBITDA, increased 15.5% year-on-year to Rs 3,332 crore in the quarter.
Investors are anticipating the announcement of the drugmaker's quarterly results on July 26.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
